Grace Therapeutics has successfully secured $10 million in private Placement financing, extending its cash runway until 2028. This financial boost is critical for the company as it prepares for the resubmission of its New Drug Application (NDA) for GTx-104.
Key Highlights
- Cash reserves of $22.2 million will support NDA resubmission efforts through 2028.
- Grace Therapeutics, Inc. (NASDAQ: GRCE) operates as a late-stage biopharmaceutical company with a market Capitalization of $34 million.
- The financing is designed to facilitate the company's ongoing work related to Manufacturing and meeting the regulatory requirements necessary for advancing GTx-104.
Grace Therapeutics, Inc. (NASDAQ: GRCE) operates as a late-stage biopharmaceutical company with a market capitalization of $34 million. It is specifically focused on developing GTx-104, an injectable formulation aimed at progressing through the regulatory gauntlet for treating aneurysmal subarachnoid hemorrhage (aSAH). Recently, the company announced a significant $10 million funding raise, a move that extends its cash runway through the end of 2028.
This extension is important as it will support the regulatory requirements and manufacturing preparations needed for the resubmission of its New Drug Application (NDA).
Funding Details
The financing is designed to facilitate the company's ongoing work related to manufacturing and meeting the regulatory requirements necessary for advancing GTx-104. This sum represents about 29% of the firm's current market capitalization. Given that Grace Therapeutics has not reported any Revenue over the past twelve months, securing this funding is key as it will ensure the company can continue its operational activities while simultaneously working toward addressing the items cited in the FDA's Complete Response Letter (CRL).
This strategic capital injection also allows for flexibility as the company navigates dual-source manufacturing strategies amidst current regulatory scrutiny.
Financial Health Analysis
As of early August, Grace Therapeutics reported cash and cash equivalents totaling $22.2 million, providing a buffer for ongoing activities needed to rectify issues noted in the FDA's CRL. This increase in losses included a $13.5 million impairment. Despite this dip, the firm has effectively managed its operational expenditures, reducing administrative costs to $1.7 million from $2.1 million a year ago.
The ability to sustain operational spending while planning for NDA resubmission demonstrates a commitment to managing this challenging period within the pharmaceutical regulatory environment.
Market Context
Trading indicators reveal that the shares are below their 20-day Moving Average of $2.21, as well as below both the 50-day and 200-day moving averages of $2.30 and $3.15 respectively. Immediate technical support lies at $1.76 while the next resistance level is observed at $2.49, highlighting the Volatility and uncertainty surrounding the stock's future trajectory as the company maneuvers through its regulatory hurdles.
Upcoming Catalysts
Upcoming corporate milestones will be closely monitored, particularly the actions stemming from Grace Therapeutics' obligation to address the FDA's CRL. The timeline and readiness of the dual manufacturing strategies will significantly influence operational execution and potential market reactions. Stakeholders will be attentive to further developments on August 11, considering this date coincides with the next significant opportunity for the company to communicate its progress through requirements outlined in the CRL, potentially impacting the direction of shares moving forward.
Peers Moving on This News
- Veru Inc (NASDAQ: VERU) down 1.6%
- MIRA Pharmaceuticals Inc (NASDAQ: MIRA) up 4.2%






Please wait processing your request...